CAMBRIDGE INNOVATION TECHNOLOGIES CONSULTING LIMITED

Their core work

CITC Ltd is a Cambridge-based technology consulting SME specializing in biomedical engineering, advanced drug delivery systems, and in vitro disease modeling. Their work spans designing nanoparticle-based therapeutic systems for cardiovascular applications and building 3D biofabricated tissue models for cancer research and drug screening. They contribute technical consulting and engineering expertise to research consortia, bridging the gap between laboratory science and applied biomedical technology. Their core value lies in translating complex biological challenges — inhaled drug delivery, cancer metastasis modeling — into engineered, testable systems.

What they specialise in

How they've shifted over time

In their early H2020 work (2017), CITC focused on cardiovascular drug delivery — specifically engineering bioinspired nanoparticles for inhalation-based, needle-free treatment. By 2018, their focus shifted toward oncology and tissue engineering, with an emphasis on 3D bioprinted cancer models, microfluidics, and high-throughput drug screening for personalised medicine. The trajectory is clear: from particle-level drug delivery engineering toward organ/tissue-level disease modeling and screening platforms.

CITC is moving toward complex in vitro disease platforms — bioprinted tissue models and microfluidic systems — suggesting future collaboration opportunities in personalised oncology, organ-on-chip, and preclinical drug testing.

How they like to work

CITC participates exclusively as a consortium partner, never as project coordinator, indicating they operate as a specialist contributor rather than a project driver. With 18 unique partners across 2 projects, they engage in relatively large consortia averaging 9 partners per project. This suggests they are comfortable working within complex multi-partner research teams and likely contribute a defined technical or consulting scope rather than leading overall project management.

CITC has collaborated with 18 unique partners across 9 countries in just 2 projects, reflecting access to broad European research networks despite their small size. Their partnerships span both FET and NMBP funding lines, suggesting connections across frontier research and applied nanotechnology communities.

What sets them apart

CITC occupies a rare niche as a private consulting SME in Cambridge with hands-on expertise in both nanoparticle drug delivery and 3D tissue engineering — two areas that rarely sit under the same roof at this scale. Their position as a small, agile consultancy embedded in the Cambridge biomedical ecosystem makes them a practical bridge between academic research consortia and translational applications. For consortium builders, they offer specialist technical input without the overhead of a large institution.

Highlights from their portfolio

• CUPIDO
  Largest funding received (EUR 314,914) and addresses a compelling engineering challenge — inhaled nanoparticles as a needle-free cardiovascular drug delivery route, combining materials science with clinical application.
• B2B
  First-of-its-kind 3D device to model breast cancer bone metastasis, combining bioprinting, microfluidics, and personalised medicine in a single platform — high translational and commercial relevance.